PATH | VRL
Menu

Characterization and Standardization of Sabin Based Inactivated Polio Vaccine: Proposal for a New Antigen Unit for Inactivated Polio Vaccines

To prepare for the post-eradication period of polio and meet expected demand for inactivated polio vaccine (IPV), the production capacity of wild-type IPV needs to increase. However, the strains used for this process require stringent containment measures, which restricts production to industrialized countries. Different studies have reported the poor immunogenicity of Sabin-based IPV and the lack of comparability between wild-type IPV and Sabin IPV with regard to antigenicity. The authors of this article, published in Vaccine, have extended the study on antigenic and immunogenic properties of Sabin IPV with a panel of monoclonal antibodies and two different methods to come to a precise antigenic fingerprint of Sabin IPV. Based on the results of this characterization and standardization study, the authors propose a better defined unit for IPVs. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Westdijk J, Brugmans D, Martin J, et al.

Published: 2011

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Westdijk J, Brugmans D, Martin J, et al. Characterization and Standardization of Sabin Based Inactivated Polio Vaccine: Proposal for a New Antigen Unit for Inactivated Polio Vaccines. Vaccine. 2011;29(18):3390-3397.

Resource types: Peer-reviewed journal

Diseases/vaccines: Polio

Topics: Disease/vaccine specific information

Regions: Global